id	sid	eid	entity	type
gs-1727	1	1	georgian	NORP
gs-1727	1	2	მეცნიერები	GPE
gs-1727	1	3	5	CARDINAL
gs-1727	1	4	2023 109	CARDINAL
gs-1727	1	5	georgian	NORP
gs-1727	1	6	მეცნიერები	GPE
gs-1727	2	1	5	CARDINAL
gs-1727	2	2	2	CARDINAL
gs-1727	2	3	2023 https://doi.org/10.52340/gs.2023.05.02.14	ORG
gs-1727	2	4	iib	PRODUCT
gs-1727	2	5	bidzina kulumbegov1,2	PERSON
gs-1727	2	6	gotua1	ORG
gs-1727	3	1	2tbilisi	CARDINAL
gs-1727	3	2	1	CARDINAL
gs-1727	3	3	iib	PRODUCT
gs-1727	3	4	csu	NORP
gs-1727	4	1	september 2019 to december 2022	DATE
gs-1727	4	2	tbilisi	GPE
gs-1727	4	3	georgia	GPE
gs-1727	4	4	39	CARDINAL
gs-1727	4	5	95%	PERCENT
gs-1727	4	6	5%	PERCENT
gs-1727	4	7	age 35.82 years	DATE
gs-1727	5	1	ige	PERSON
gs-1727	5	2	ana	PERSON
gs-1727	7	1	4 weeks	DATE
gs-1727	7	2	at least 3 months	DATE
gs-1727	8	1	uas7	PERSON
gs-1727	8	2	three	CARDINAL
gs-1727	8	3	csu	NORP
gs-1727	10	1	iib	PERSON
gs-1727	10	2	55.5%	PERCENT
gs-1727	10	3	18.3%	PERCENT
gs-1727	11	1	iib	PRODUCT
gs-1727	11	2	72.7%	PERCENT
gs-1727	11	3	18.5%	PERCENT
gs-1727	12	1	iib	PRODUCT
gs-1727	12	2	138	CARDINAL
gs-1727	12	3	23.95 ku	QUANTITY
gs-1727	13	1	iib	PRODUCT
gs-1727	13	2	9	CARDINAL
gs-1727	13	3	27 months	DATE
gs-1727	14	1	two	CARDINAL
gs-1727	14	2	eosinopenia	DATE
gs-1727	16	1	iib	PERSON
gs-1727	17	1	iib	PRODUCT
gs-1727	19	1	iib autoimmunity	PERSON
gs-1727	19	2	georgian	NORP
gs-1727	19	3	მეცნიერები	GPE
gs-1727	19	4	5	CARDINAL
gs-1727	19	5	2023	CARDINAL
gs-1727	19	6	csu	NORP
gs-1727	19	7	manufacturer1	ORG
gs-1727	20	1	around 70%	PERCENT
gs-1727	20	2	uas7	PERSON
gs-1727	20	3	an additional 15%	PERCENT
gs-1727	20	4	3-4 months	DATE
gs-1727	21	1	the remaining 15%	PERCENT
gs-1727	21	2	treatment2	GPE
gs-1727	22	1	3,4	CARDINAL
gs-1727	23	1	csu	NORP
gs-1727	23	2	omalizumab5	ORG
gs-1727	24	1	iib	PRODUCT
gs-1727	24	2	6	CARDINAL
gs-1727	24	3	two	CARDINAL
gs-1727	24	4	two	CARDINAL
gs-1727	24	5	csu	NORP
gs-1727	25	1	first	ORDINAL
gs-1727	25	2	second	ORDINAL
gs-1727	25	3	iib autoimmune csu	ORG
gs-1727	25	4	iga	ORG
gs-1727	26	1	asst	ORG
gs-1727	26	2	basophil	ORG
gs-1727	26	3	two	CARDINAL
gs-1727	28	1	ige	PERSON
gs-1727	28	2	ana	PERSON
gs-1727	29	1	iib	PERSON
gs-1727	29	2	two	CARDINAL
gs-1727	30	1	september 2019 to december 2022	DATE
gs-1727	30	2	tbilisi	GPE
gs-1727	30	3	georgia	GPE
gs-1727	31	1	thirty-nine	CARDINAL
gs-1727	31	2	12 years old	DATE
gs-1727	31	3	csu	NORP
gs-1727	31	4	guideline1	PERSON
gs-1727	33	1	4 weeks	DATE
gs-1727	33	2	at least three months	DATE
gs-1727	34	1	georgian	NORP
gs-1727	34	2	მეცნიერები	GPE
gs-1727	34	3	5	CARDINAL
gs-1727	34	4	2023 111	CARDINAL
gs-1727	34	5	two	CARDINAL
gs-1727	35	1	ige	PERSON
gs-1727	35	2	ana	PERSON
gs-1727	36	1	first	ORDINAL
gs-1727	36	2	43 ku/l	QUANTITY
gs-1727	36	3	iib	PRODUCT
gs-1727	36	4	ige	PERSON
gs-1727	36	5	43 ku	MONEY
gs-1727	36	6	ana	PERSON
gs-1727	37	1	uas	ORG
gs-1727	37	2	1	CARDINAL
gs-1727	37	3	2	CARDINAL
gs-1727	37	4	3	CARDINAL
gs-1727	37	5	20	CARDINAL
gs-1727	37	6	1	CARDINAL
gs-1727	37	7	2	CARDINAL
gs-1727	37	8	50	CARDINAL
gs-1727	37	9	3	CARDINAL
gs-1727	37	10	seven consecutive days	DATE
gs-1727	37	11	uas7	PERSON
gs-1727	37	12	0	CARDINAL
gs-1727	37	13	42	CARDINAL
gs-1727	38	1	uas7	PERSON
gs-1727	38	2	less than 30%	PERCENT
gs-1727	38	3	uas7	PERSON
gs-1727	38	4	30% to 89%	PERCENT
gs-1727	38	5	90%	PERCENT
gs-1727	38	6	uas7	PERSON
gs-1727	39	1	uppsala	GPE
gs-1727	39	2	sweden	GPE
gs-1727	40	1	ana	PERSON
gs-1727	42	1	ana	PERSON
gs-1727	42	2	1:80	DATE
gs-1727	43	1	34 ku/l	QUANTITY
gs-1727	44	1	serum crp	PERSON
gs-1727	44	2	6.0 mg/l	QUANTITY
gs-1727	48	1	±	CARDINAL
gs-1727	49	1	spss	ORG
gs-1727	49	2	22.0	CARDINAL
gs-1727	49	3	ibm	ORG
gs-1727	49	4	new york	GPE
gs-1727	50	1	0.05	CARDINAL
gs-1727	51	1	39	CARDINAL
gs-1727	51	2	95%	PERCENT
gs-1727	51	3	n=37	GPE
gs-1727	51	4	5%	PERCENT
gs-1727	52	1	age 35.82 years	DATE
gs-1727	52	2	12	CARDINAL
gs-1727	53	1	iib	PERSON
gs-1727	53	2	55.5%	PERCENT
gs-1727	53	3	18.3%	PERCENT
gs-1727	54	1	iib	PRODUCT
gs-1727	54	2	72.7%	PERCENT
gs-1727	54	3	18.5%	PERCENT
gs-1727	55	1	iib	PRODUCT
gs-1727	55	2	138	CARDINAL
gs-1727	55	3	23.95 ku	QUANTITY
gs-1727	56	1	iib	PRODUCT
gs-1727	56	2	9	CARDINAL
gs-1727	56	3	27 months	DATE
gs-1727	57	1	two	CARDINAL
gs-1727	57	2	eosinopenia	DATE
gs-1727	58	1	1	CARDINAL
gs-1727	59	1	georgian	NORP
gs-1727	59	2	მეცნიერები	GPE
gs-1727	59	3	5	CARDINAL
gs-1727	59	4	2023 112	CARDINAL
gs-1727	59	5	1	CARDINAL
gs-1727	60	1	group1	PERSON
gs-1727	60	2	43	CARDINAL
gs-1727	60	3	ana -	PERSON
gs-1727	60	4	2	CARDINAL
gs-1727	60	5	iib	ORG
gs-1727	60	6	ana +	PERSON
gs-1727	60	7	92%	PERCENT
gs-1727	60	8	100%	PERCENT
gs-1727	60	9	age (years	DATE
gs-1727	60	10	±	CARDINAL
gs-1727	60	11	34.63	CARDINAL
gs-1727	60	12	0.368	CARDINAL
gs-1727	60	13	55.5%	PERCENT
gs-1727	60	14	18.3%	PERCENT
gs-1727	60	15	0.004	CARDINAL
gs-1727	60	16	26%	PERCENT
gs-1727	60	17	9%	PERCENT
gs-1727	60	18	18.5%	PERCENT
gs-1727	60	19	0.012	CARDINAL
gs-1727	60	20	42%	PERCENT
gs-1727	60	21	60%	PERCENT
gs-1727	60	22	(month	DATE
gs-1727	60	23	9 27 0.019	TIME
gs-1727	60	24	ige ku	PERSON
gs-1727	60	25	138	CARDINAL
gs-1727	60	26	23.95	CARDINAL
gs-1727	60	27	0.02	CARDINAL
gs-1727	60	28	24.57	CARDINAL
gs-1727	60	29	+ 32%	PERCENT
gs-1727	60	30	27%	PERCENT
gs-1727	60	31	0.085	CARDINAL
gs-1727	60	32	+ 50%	PERCENT
gs-1727	60	33	36.6%	PERCENT
gs-1727	60	34	0.867 eosinopenia	DATE
gs-1727	60	35	0.05	CARDINAL
gs-1727	60	36	0.24 0.21 0.847	QUANTITY
gs-1727	60	37	0.01	CARDINAL
gs-1727	60	38	0.06 0.02	CARDINAL
gs-1727	60	39	georgian	NORP
gs-1727	60	40	მეცნიერები	GPE
gs-1727	60	41	5	CARDINAL
gs-1727	60	42	2023 113	DATE
gs-1727	60	43	1	CARDINAL
gs-1727	60	44	iib	PRODUCT
gs-1727	61	1	two	CARDINAL
gs-1727	61	2	43 ku	MONEY
gs-1727	61	3	iib	PRODUCT
gs-1727	61	4	ige	PERSON
gs-1727	61	5	43 ku	MONEY
gs-1727	61	6	ana	PERSON
gs-1727	63	1	iib	PRODUCT
gs-1727	63	2	iib	PRODUCT
gs-1727	63	3	i.	PERSON
gs-1727	63	4	iib	PRODUCT
gs-1727	63	5	iib	PRODUCT
gs-1727	64	1	two	CARDINAL
gs-1727	64	2	eosinopenia	DATE
gs-1727	65	1	2	CARDINAL
gs-1727	65	2	iib	PERSON
gs-1727	65	3	csu	NORP
gs-1727	66	1	2	CARDINAL
gs-1727	66	2	csu	NORP
gs-1727	67	1	two	CARDINAL
gs-1727	67	2	csu	NORP
gs-1727	67	3	8	CARDINAL
gs-1727	68	1	iib	PRODUCT
gs-1727	68	2	9,10	CARDINAL
gs-1727	70	1	43	CARDINAL
gs-1727	70	2	week 4	DATE
gs-1727	70	3	csu	NORP
gs-1727	70	4	week 12	DATE
gs-1727	71	1	weller et al.	PERSON
gs-1727	71	2	77.5%	PERCENT
gs-1727	71	3	20%	PERCENT
gs-1727	72	1	asero	PERSON
gs-1727	72	2	ige 13	ORG
gs-1727	73	1	csu	NORP
gs-1727	74	1	csu	NORP
gs-1727	79	1	csu	NORP
gs-1727	80	1	csu	NORP
gs-1727	81	1	georgian	GPE
gs-1727	81	2	მეცნიერები	GPE
gs-1727	81	3	5	CARDINAL
gs-1727	81	4	2023 114	CARDINAL
gs-1727	81	5	csu	NORP
gs-1727	81	6	iib	PRODUCT
gs-1727	82	1	iib	PRODUCT
gs-1727	82	2	iib	PRODUCT
gs-1727	82	3	i.	PERSON
gs-1727	82	4	iib	PRODUCT
gs-1727	83	1	iib	PRODUCT
gs-1727	83	2	csu	NORP
gs-1727	84	1	ige	PERSON
gs-1727	84	2	ana	PERSON
gs-1727	84	3	two	CARDINAL
gs-1727	87	1	national science foundation	ORG
gs-1727	87	2	georgia	GPE
gs-1727	87	3	phdf-21-3221	DATE
gs-1727	88	1	1	CARDINAL
gs-1727	88	2	abdul latiff	PERSON
gs-1727	90	1	2022	CARDINAL
gs-1727	90	2	77:734	CARDINAL
gs-1727	91	1	2	CARDINAL
gs-1727	91	2	gericke j	PERSON
gs-1727	91	3	metz m	PERSON
gs-1727	91	4	ohanyan t	PERSON
gs-1727	93	1	clin immunol 2017;139:105961.	PERSON
gs-1727	94	1	3	CARDINAL
gs-1727	94	2	md	GPE
gs-1727	94	3	oliver e	PERSON
gs-1727	94	4	palacios t	PERSON
gs-1727	94	5	serum ige	PERSON
gs-1727	95	1	clin immunol pract 2018;6:1386-88	ORG
gs-1727	95	2	4	CARDINAL
gs-1727	95	3	ozyurt k	PERSON
gs-1727	95	4	maurer m.	PERSON
gs-1727	96	1	2018;73:705-12	CARDINAL
gs-1727	96	2	5	CARDINAL
gs-1727	97	1	schmetzer o	PERSON
gs-1727	97	2	lakin e	PERSON
gs-1727	97	3	topal fa	PERSON
gs-1727	97	4	al. il-24	GPE
gs-1727	98	1	clin immunol 2018;142:876-82	PERSON
gs-1727	98	2	6	CARDINAL
gs-1727	99	1	kolkhir p	ORG
gs-1727	99	2	altrichter s	PERSON
gs-1727	99	3	ferrer m	ORG
gs-1727	99	4	jakob t	PERSON
gs-1727	99	5	kinaciyan	GPE
gs-1727	99	6	t, kromminga	GPE
gs-1727	99	7	konstantinou gn	PERSON
gs-1727	99	8	makris m	PERSON
gs-1727	99	9	metz m	PERSON
gs-1727	99	10	staubach	PERSON
gs-1727	99	11	georgian	NORP
gs-1727	99	12	მეცნიერები	GPE
gs-1727	99	13	5	CARDINAL
gs-1727	99	14	2023	CARDINAL
gs-1727	99	15	zhang k	PERSON
gs-1727	99	16	maurer m. autoimmune	ORG
gs-1727	99	17	iib	ORG
gs-1727	101	1	2021jul;13(4):545-559	CARDINAL
gs-1727	102	1	7	CARDINAL
gs-1727	102	2	agondi rc	PERSON
gs-1727	102	3	ojeda i. urticaria	PERSON
gs-1727	103	1	indian	NORP
gs-1727	103	2	2022;1:35	CARDINAL
gs-1727	104	1	maurer m	ORG
gs-1727	104	2	ferrer m	ORG
gs-1727	104	3	hartmann k	PERSON
gs-1727	104	4	jakob t	PERSON
gs-1727	104	5	kapp a	ORG
gs-1727	104	6	larenas-linnemann	PERSON
gs-1727	104	7	-s	NORP
gs-1727	104	8	schäkel k	PERSON
gs-1727	104	9	simon h	PERSON
gs-1727	104	10	weller k	PERSON
gs-1727	104	11	metz m	PERSON
gs-1727	104	12	collegium internationale allergologicum	PERSON
gs-1727	104	13	cia	ORG
gs-1727	104	14	2020	DATE
gs-1727	105	1	2020;181:321-333	CARDINAL
gs-1727	106	1	9	CARDINAL
gs-1727	106	2	erol k	ORG
gs-1727	106	3	ş, maurer m.	GPE
gs-1727	106	4	csu	NORP
gs-1727	108	1	2020	DATE
gs-1727	108	2	470	CARDINAL
gs-1727	109	1	10	CARDINAL
gs-1727	109	2	zhiron du	PERSON
gs-1727	109	3	yuxiang zhi	PERSON
gs-1727	109	4	md.	GPE
gs-1727	109	5	chrinic spontaneus urticaria.	ORG
gs-1727	110	1	151	CARDINAL
gs-1727	110	2	2	CARDINAL
gs-1727	110	3	february 2023.	DATE
gs-1727	111	1	ozyurt k	PERSON
gs-1727	111	2	maurer m.	PERSON
gs-1727	112	1	2018;73(3):705	CARDINAL
gs-1727	112	2	12	CARDINAL
gs-1727	113	1	weller k	PERSON
gs-1727	113	2	ohanyan t	GPE
gs-1727	115	1	2018;73(12):2406-2408	ORG
gs-1727	116	1	13	CARDINAL
gs-1727	116	2	r. chronic	PERSON
gs-1727	117	1	eur ann allergy clin immunol.	PERSON
gs-1727	118	1	2020	DATE
gs-1727	119	1	14	CARDINAL
gs-1727	119	2	r.	NORP
gs-1727	119	3	s. m.	PERSON
gs-1727	119	4	calzari	PERSON
gs-1727	119	5	consonni	GPE
gs-1727	119	6	d., & cugno	ORG
gs-1727	119	7	m.	PERSON
gs-1727	119	8	2023	CARDINAL
gs-1727	120	1	csu	NORP
gs-1727	121	1	24(8	CARDINAL
gs-1727	122	1	iib	ORG
gs-1727	122	2	2	CARDINAL
gs-1727	122	3	2თბილისის სახელმწიფო	ORG
gs-1727	124	1	კლინიკური პასუხის	PERSON
gs-1727	124	2	39	CARDINAL
gs-1727	124	3	95%	PERCENT
gs-1727	124	4	5%	PERCENT
gs-1727	124	5	35.82	CARDINAL
gs-1727	124	6	2019	CARDINAL
gs-1727	124	7	2022	CARDINAL
gs-1727	124	8	იმუნოლოგიის ცენტრში	WORK_OF_ART
gs-1727	125	1	მარკერებად გამოვიყენეთ	PERSON
gs-1727	125	2	ana ანტისხეულების არსებობა.	ORG
gs-1727	125	3	კვლევაში შედიოდნენ	PERSON
gs-1727	125	4	რომლებსაც	ORG
gs-1727	125	5	არასედაციური georgian scientists/ქართველი	GPE
gs-1727	125	6	მეცნიერები	GPE
gs-1727	125	7	5	CARDINAL
gs-1727	125	8	2023 116	CARDINAL
gs-1727	125	9	დოზით	NORP
gs-1727	125	10	მიუხედავად	GPE
gs-1727	125	11	ჰქონდათ	GPE
gs-1727	125	12	საერთაშორისო	ORG
gs-1727	125	13	4	CARDINAL
gs-1727	125	14	კვირის ინტერვალით	PERSON
gs-1727	125	15	3	CARDINAL
gs-1727	125	16	uas7	PERSON
gs-1727	126	1	მიხედვით პაციენტები დაიყო	ORG
gs-1727	126	2	არამოპასუხე	ORG
gs-1727	126	3	ნაწილობრივ მოპასუხე	ORG
gs-1727	126	4	მოპასუხე.	CARDINAL
gs-1727	126	5	შედეგებმა აჩვენა	PERSON
gs-1727	127	1	შემთხვევაში სრულად მოპასუხე	ORG
gs-1727	127	2	პროცენტული მაჩვენებელი სტატისტიკურად სარწმუნოდ მაღალია	ORG
gs-1727	127	3	55.5%/18.3%	PERCENT
gs-1727	128	1	ომალიზუმაბზე არამოპასუხეთა	PERSON
gs-1727	128	2	72.7%/18.5%	PERCENT
gs-1727	129	1	საერთო ige დონე მნიშვნელოვნად	PERSON
gs-1727	130	1	138	CARDINAL
gs-1727	130	2	23.95 ku	QUANTITY
gs-1727	131	1	9	CARDINAL
gs-1727	131	2	27	CARDINAL
gs-1727	132	1	დაფიქსირებულა ასაკის	PERSON
gs-1727	132	2	igg დონის	ORG
gs-1727	132	3	ბაზოპენიის	ORG
gs-1727	132	4	თვალსაზრისით. შეიძლება	PERSON
gs-1727	132	5	დავასკვნათ	PERSON
gs-1727	136	1	ჯგუფში	GPE
gs-1727	136	2	შეფასდეს მექანიზმი	ORG
gs-1727	138	1	სპოინტანური ურტიკარია	PERSON